

Richard E K Russell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4258597/publications.pdf>

Version: 2024-02-01

52
papers

2,990
citations

489802

18
h-index

312153

41
g-index

56
all docs

56
docs citations

56
times ranked

3862
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 545-556.	5.2	30
2	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 763-772.	5.2	301
3	Predicting treatment outcomes following an exacerbation of airways disease. <i>PLoS ONE</i> , 2021, 16, e0254425.	1.1	3
4	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <i>Lancet</i> , 2021, 398, 843-855.	6.3	204
5	Renaming COPD exacerbations: the UK respiratory nursing perspective. <i>BMC Pulmonary Medicine</i> , 2021, 21, 299.	0.8	2
6	A new piece in the puzzle: the eosinophil and the development of COPD. <i>European Respiratory Journal</i> , 2021, 58, 2101105.	3.1	4
7	30-day Readmission After an Acute Exacerbation of Chronic Obstructive Pulmonary Disease is Associated with Cardiovascular Comorbidity. , 2021, 22, 369-375.		2
8	Discordant diagnostic criteria for pneumonia in COPD trials: a review. <i>European Respiratory Review</i> , 2021, 30, 210124.	3.0	8
9	In the race at last: post-hoc analysis of GALATHEA and TERRANOVA. <i>Lancet Respiratory Medicine</i> , 2020, 8, 127-129.	5.2	1
10	Exacerbations of chronic obstructive pulmonary disease: time to rename. <i>Lancet Respiratory Medicine</i> , 2020, 8, 133-135.	5.2	13
11	Finding the true prevalence of obstructive lung disease: two steps forward and one step back. <i>European Respiratory Journal</i> , 2020, 55, 2001514.	3.1	1
12	<p>Covid-19 and COPD: A Personal Reflection</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 883-884.	0.9	5
13	Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD. <i>European Respiratory Journal</i> , 2020, 55, 1902412.	3.1	0
14	<p>The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 971-977.	0.9	8
15	<p>â€œBreathing New Life Into Chronic Obstructive Pulmonary Disease (COPD)â€•â€œ Results From An Online Survey Of UK Patients</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2799-2807.	0.9	3
16	The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate. <i>Turkish Thoracic Journal</i> , 2019, 20, 198-202.	0.2	0
17	What will Happen in the World of COPD 2030?. <i>Turkish Thoracic Journal</i> , 2019, 20, 153-257.	0.2	0
18	What Does the TOVITO Programme Tell Us about How We Can Manage COPD?. <i>Turkish Thoracic Journal</i> , 2018, 19, 216-219.	0.2	3

#	ARTICLE	IF	CITATIONS
19	Toward effective prescription of inhaled corticosteroids in chronic airway disease. International Journal of COPD, 2018, Volume 13, 3419-3424.	0.9	2
20	Investigating blood eosinophil count thresholds in patients with COPD. Lancet Respiratory Medicine, 2018, 6, 823-824.	5.2	5
21	Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine, 2017, 128, 28-41.	1.3	15
22	Eosinophils in COPD: just another biomarker?. Lancet Respiratory Medicine, 2017, 5, 747-759.	5.2	160
23	Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects. International Journal of COPD, 2017, Volume 12, 2771-2775.	0.9	9
24	Are COPD and cardiovascular disease fundamentally intertwined?. European Respiratory Journal, 2016, 47, 1307-1309.	3.1	6
25	Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. European Respiratory Journal, 2016, 47, 1093-1102.	3.1	53
26	Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. PLoS ONE, 2016, 11, e0162903.	1.1	43
27	Chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2014, 20, 127-131.	1.2	7
28	Children must be protected from the tobacco industry's marketing tactics. BMJ, 2013, 347, f7358-f7358.	3.0	2
29	Management of acute asthma in the UK: Table 1. Emergency Medicine Journal, 2013, 30, 864.2-864.	0.4	0
30	Management Strategies. , 2013, , 43-57.		0
31	The Future of COPD. , 2013, , 77-92.		0
32	Expression of muscarinic receptors by human macrophages. European Respiratory Journal, 2012, 39, 698-704.	3.1	53
33	Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. International Journal of COPD, 2011, 6, 47.	0.9	8
34	The Future of COPD. , 2011, , 75-90.		1
35	Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD. Chest, 2010, 137, 1338-1344.	0.4	166
36	Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 75-83.	2.5	42

#	ARTICLE	IF	CITATIONS
37	Noninvasive ventilation: has Pandora's box been opened?. International Journal of COPD, 2010, 5, 55.	0.9	4
38	Expression of Transient Receptor Potential C6 Channels in Human Lung Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 296-304.	1.4	55
39	ICS and COPD: Time to clear the air. International Journal of COPD, 2009, 4, 289.	0.9	3
40	Impact factor and its role in academic promotion. International Journal of COPD, 2009, 4, 265.	0.9	7
41	Leukotriene B4 release by human lung macrophages via receptor- not voltage-operated Ca ²⁺ channels. European Respiratory Journal, 2009, 33, 1105-1112.	3.1	11
42	Management of Exacerbation of COPD. Acute Medicine, 2008, 7, 21-7.	0.1	0
43	The Role of IÎB Kinase 2, but Not Activation of NF-ÎB, in the Release of CXCR3 Ligands from IFN-Î ³ -Stimulated Human Bronchial Epithelial Cells. Journal of Immunology, 2007, 179, 6237-6245.	0.4	43
44	Which bronchodilator in COPD?. International Journal of COPD, 2007, 2, 93-4.	0.9	0
45	The big picture and the little picture. International Journal of COPD, 2006, 1, 97-97.	0.9	0
46	Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 287, L774-L783.	1.3	297
47	Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax, 2003, 58, 942-946.	2.7	185
48	Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 24-31.	2.5	281
49	Matrix Metalloproteinase-9 Expression in Asthma. Chest, 2002, 122, 1543-1552.	0.4	162
50	Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L867-L873.	1.3	208
51	Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 602-609.	1.4	386
52	Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1371-1376.	2.5	163